Compare CLFD & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | CLFD | LXEO |
|---|---|---|
| Founded | 1979 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | |
| Sector | Utilities | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 402.8M | 396.5M |
| IPO Year | 1995 | 2023 |
| Metric | CLFD | LXEO |
|---|---|---|
| Price | $30.54 | $4.67 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 9 |
| Target Price | ★ $43.50 | $18.44 |
| AVG Volume (30 Days) | 170.0K | ★ 1.0M |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 31.76 | ★ 39.81 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $85,034,000.00 | $654,000.00 |
| Revenue This Year | $11.64 | N/A |
| Revenue Next Year | $22.30 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 9.51 | N/A |
| 52 Week Low | $23.76 | $3.91 |
| 52 Week High | $52.73 | $10.99 |
| Indicator | CLFD | LXEO |
|---|---|---|
| Relative Strength Index (RSI) | 35.18 | 47.48 |
| Support Level | $28.61 | $4.30 |
| Resistance Level | $30.99 | $5.36 |
| Average True Range (ATR) | 1.38 | 0.35 |
| MACD | -0.12 | 0.01 |
| Stochastic Oscillator | 16.35 | 26.02 |
Clearfield Inc designs, manufactures, and distributes fiber protection, fiber management, and fiber delivery solutions to enable rapid and cost-effective fiber-fed deployment throughout the broadband service provider space prominently across North America. Its 'fiber to anywhere' platform serves the requirements of Community Broadband customers, Multiple System Operators, Large Regional Service Providers, National Carriers, and International customers (including Europe, Canada, Mexico, and Caribbean Markets). Its product offerings include Accessories, Cassettes, Cable & Drop Assemblies, Frames & Panels, Microducts, Optical Components, etc. The company derives the majority of its revenue from the United States.
Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.